August 12, 2025Therapeutic Advances in GastroenterologyOpen Access

Short- and longevity outcome of cyclosporin rescue therapy in severe ulcerative colitis refractory to intravenous corticosteroid treatment

View Full Paper

Ask AI

Bookmark

Authors

BFB Farkas PBP Bacsúr ABAnita Bálint

Discussion

Member takes

Implication

Retrospective study highlights colectomy-free survival rates and remission in severe ulcerative colitis patients treated with cyclosporin and immunomodulators.

Key Points

Clinical response was achieved in 88% of patients receiving cyclosporin treatment for severe ulcerative colitis.
The probability of colectomy-free survival at 1, 5, and 14 years were 74.7%, 57.1%, and 45.6%, respectively, indicating long-term effectiveness.
Adverse events were reported in 53.3% of patients, with hyperlipidaemia and hypertension being the most common complications.
Concomitant use of immunomodulators significantly increased the likelihood of achieving clinical remission during cyclosporin therapy.

Cite This Study

Farkas et al. (2025) studied this question.

synapsesocial.com/papers/68c23595b210217d64771328 https://doi.org/10.1177/17562848251361054

View Full Paper

Ask AI

Bookmark

Implication

Retrospective study highlights colectomy-free survival rates and remission in severe ulcerative colitis patients treated with cyclosporin and immunomodulators.

Short- and longevity outcome of cyclosporin rescue therapy in severe ulcerative colitis refractory to intravenous corticosteroid treatment

Discussion

Member takes

Implication

Key Points

Cite This Study

Short- and longevity outcome of cyclosporin rescue therapy in severe ulcerative colitis refractory to intravenous corticosteroid treatment

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider